18 nov: Scor 400.000 på din pension
19 nov: Den vildeste Porsche
19-11-2010 10:37:27

AstraZeneca confirms eyeing Astra Tech spin-off

Relateret indhold

LONDON (Reuters) - AstraZeneca (Astrazeneca PLC ORD SHS $0.25) confirmed on Friday it was considering spinning off its Astra Tech dental implants and medical devices business and had hired JP Morgan Chase (JPMorgan Chase & Co) to help with a strategic review of the unit.

A source familiar with the situation said earlier this week that the Anglo-Swedish drugmaker was looking to sell the non-core Swedish-based business for some $2 billion (1.2 billion pounds) after hiring the bank as adviser.

"AstraZeneca continues to evaluate all alternatives for value maximisation from this business and any final decision will only be made when the results of the review have concluded," the company said in a brief statement.

A company spokeswoman confirmed that a sale of the operation was one option. She declined to comment on the timing of any decision.

The expected sale of Astra Tech highlights AstraZeneca's current focus on boosting returns as the group heads into a wave of patent expiries on some of its biggest-selling medicines.

In contrast to some of its rivals -- such as GlaxoSmithKline (GlaxoSmithKline PLC), Novartis and Sanofi-Aventis -- AstraZeneca has stayed focussed on its core pharmaceuticals business rather than seeking diversification.

Shares in the company were barely changed by 9:30 a.m., down 0.3 percent at 3053.5 pence, in line with a flat Stoxx 600 European healthcare sector index .

The Astra Tech business could be of interest to U.S. companies such as privately held Biomet, Medtronic (Medtronic Inc), 3M (3M Co), Danaher (Danaher Corp) and Dentsply International (Dentsply International Inc), as well as private equity firms, according to industry analysts.

Companies operating in the sector in Europe include Swiss dental implant firms Nobel Biocare and Straumann .

Astra Tech, best known for dental implants, also sells urological catheters, breathing aids and blood management systems used in surgery. It has 2,200 employees worldwide and produced revenue in 2009 of $506 million, AstraZeneca said.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Fortsat usikkerhed kan presse markedet

02-10-2014 08:38:41
Selvom fjerde kvartal normalt er aktieårets bedste, så tyder starten indtil videre ikke på det. På kvartalets første handelsdag onsdag faldt aktierne, og det te..

Nordnet: Private kaster deres kærlighed på Novo og Mærsk

01-10-2014 12:53:00
A.P. Møller - Mærsk og Novo Nordisk var Nordnet-kundernes foretrukne aktiekøb i september, hvor Vestas til gengæld var at finde på salgslisten. Det fremgår af e..

Novo: Amerikansk entreprenør skal bygge ny Bagsværd-fabrik

01-10-2014 09:17:16
Det bliver det amerikanske entreprenørselskab Jacobs Engineering Group, der skal opføre den finrensningsfabrik, som Novo Nordisk er på vej til at etablere i Bag..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Barclays: Ordreskuffelse drevet af USA og EM
2
Nordnet: Private kaster deres kærlighed på Novo og Mærsk
3
Aktier/tendens: Fortsat usikkerhed kan presse markedet
4
B&O Q1: Underskuddet forværres - forventninger præciseres opad
5
Onsdagens aktier: Skuffende nøgletal fra USA ødelagde humøret

Relaterede aktiekurser

GlaxoSmithKline PLC 1.413,78 0,0% Fald i aktiekurs
Astrazeneca PLC ORD SHS .. 4.359,00 0,0% Fald i aktiekurs
Straumann N 213,20 -0,3% Fald i aktiekurs
Danaher Corp 74,58 0,0% Aktiekurs uændret
JPMorgan Chase & Co 59,77 0,7% Stigning i aktiekurs
Medtronic Inc 62,47 0,0% Aktiekurs uændret
3M Co 139,18 0,0% Aktiekurs uændret
Dentsply International I.. 45,31 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
2. oktober 2014 10:25:05
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141001.1 - EUROWEB3 - 2014-10-02 10:25:05 - 2014-10-02 10:25:05 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x